title: Evaluation of Systemic Inflammatory Response Biomarkers in Patients Receiving Chemotherapy for Unresectable and Recurrent Advanced Gastric Cancer.
abstract: BACKGROUND
  The present study sought to evaluate an inflammation-based prognostic score (Glasgow prognostic score, GPS) and the neutrophil to lymphocyte ratio (NLR) as prognostic factors in patients receiving chemotherapy for advanced gastric cancer.
  
  
  METHODS
  The study enrolled 224 patients who received chemotherapy for advanced gastric cancer at the Kochi Medical School from 2007 to 2014. Clinicopathological information and systemic inflammatory response data were obtained to investigate associations between baseline cancer-related prognostic variables and survival outcomes.
  
  
  RESULTS
  The median survival time was significantly higher for patients with intestinal-type compared to diffuse-type histology (p = 0.039), a GPS 0 score compared to GPS 1 or 2 score (p = 0.004), and lower compared to higher NLR 4 (p = 0.002). Multivariate survival analysis identified high NLR 4 (HR 1.651; 95% CI 1.187-2.297; p = 0.003) and diffuse-type histology (HR 1.645; 95% CI 1.025-2.639; p = 0.039) as significant independent predictors associated with worse prognosis in the studied group of cancer patients.
  
  
  CONCLUSIONS
  NLR and histological type are independent prognostic factors for patients receiving chemotherapy for unresectable and recurrent gastric cancer.
authors.affiliation: Department of Surgery, Kochi Medical School, Kochi, Japan.
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Namikawa
authors.forename: Eri
authors.initials: E
authors.lastname: Munekage
authors.forename: Masaya
authors.initials: M
authors.lastname: Munekage
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Maeda
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Yatabe
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kitagawa
authors.forename: Michiya
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Hanazaki
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood*; D007564:Japan / Q000453:epidemiology; D053208:Kaplan-Meier Estimate; D007958:Leukocyte Count; D018655:Lymphocyte Count; D008214:Lymphocytes; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood; D009504:Neutrophils; D011379:Prognosis; D013274:Stomach Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers